Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Did you experience any of the following side effects?
(Please check all that apply.)

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Risperdal (Risperidone) Associated With Cerebrovascular

Apr 25, 2003 | Janssen Pharmaceutica and FDA revised the WARNINGS section of the prescribing information for Risperdal (risperidone), indicated for the
treatment of schizophrenia.

Cerebrovascular adverse events (e.g., stroke,
transient ischemic attack), including fatalities, were reported in patients in trials of risperidone in elderly patients with dementia-related psychosis.

In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with
risperidone compared to patients treated with placebo.

RISPERDAL has not been shown to be safe or effective in the treatment of patients with
dementia-related psychosis.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo